Innoviva (INVA) Net Income Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 32.79% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 60.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 19.97% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 47.10% |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 74.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.91% |
| Dec 31, 2025 | -10.20% |
| Sep 30, 2025 | -26.81% |
| Jun 30, 2025 | 43.85% |
| Mar 31, 2025 | -47.83% |
| Dec 31, 2024 | -20.34% |
| Sep 30, 2024 | -77.22% |
| Jun 30, 2024 | -32.25% |
| Mar 31, 2024 | -30.70% |
| Dec 31, 2023 | -27.81% |
| Sep 30, 2023 | 25.42% |
| Jun 30, 2023 | -76.31% |
| Mar 31, 2023 | -23.86% |
| Dec 31, 2022 | -29.63% |
| Sep 30, 2022 | 69.55% |
| Jun 30, 2022 | -22.56% |
| Mar 31, 2022 | -1.84% |
| Dec 31, 2021 | -26.46% |
| Sep 30, 2021 | 26.97% |
| Jun 30, 2021 | 25.11% |
| Mar 31, 2021 | 53.52% |
| Dec 31, 2020 | 35.27% |
| Sep 30, 2020 | 6.91% |
| Jun 30, 2020 | 39.82% |
| Mar 31, 2020 | 67.53% |
| Dec 31, 2019 | 32.57% |
| Sep 30, 2019 | 46.46% |
| Jun 30, 2019 | 52.93% |
| Mar 31, 2019 | 107.70% |
| Jun 30, 2017 | 41.41% |
| Mar 31, 2017 | 32.50% |
| Dec 31, 2016 | 37.60% |
| Sep 30, 2016 | 33.87% |
| Jun 30, 2016 | 33.31% |
| Mar 31, 2016 | 29.42% |
| Jun 30, 2014 | -20.12% |
| Mar 31, 2014 | -31.20% |
| Dec 31, 2013 | -28.28% |
| Sep 30, 2013 | -20.93% |
| Jun 30, 2013 | -18.80% |